Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Clinical trial NCT06132958 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06132958
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-06
- Primary completion
- 2028-01-10
- Enrollment
- 710
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.